Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

Inclusion Criteria: * Healthy male or female subjects * Aged between 18 and 50 years, inclusive, at screening * BMI between 18.0 and 32.0 kg/m², inclusive Exclusion Criteria: * History of drug abuse * Known hypersensitivity to granisetron, moxifloxacin, or related compounds, such as ciprofloxacin and levofloxacin * Sustained supine systolic blood pressure \>140 mmHg or \<100 mmHg or a diastolic blood pressure \>95 mmHg at Screening or baseline * Pulse rate at rest of \< 45 bpm or \> 100 bpm * Abnormal Screening ECG indicating a second- or third degree AV block, or one or more of the following: QRS \>120 milliseconds (ms); QTcF \> 430 (males) or 450 (females) ms; PR interval \>240 ms; any rhythm, other than sinus rhythm, interpreted to be clinically significant by the Investigator * Known history of long-QT syndrome, angina, myocardial ischemia or infarction, congestive heart failure, myocarditis, chest pain or dyspnea on exertion * Electrolyte disturbances (such as uncorrected hypokalemia/hyperkalemia, hypomagnesemia, hypocalcemia, or hypophosphatemia), idiopathic cardiomyopathy, unexplained syncope, hypertrophic cardiomyopathy, or sudden unexplained death at a young age (\< 40 years) in a first-degree relative. * Has used any medications or consumed any foods contraindicated in the protocol.